4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Stock Now Rated “Moderate Buy” by Wall Street Analysts

by · The Cerbat Gem

Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Free Report) have received an average rating of “Moderate Buy” from the eleven analysts that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has issued a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $28.56.

A number of brokerages recently issued reports on FDMT. B. Riley Financial reissued a “buy” rating on shares of 4D Molecular Therapeutics in a report on Monday, August 17th. Cantor Fitzgerald upgraded shares of 4D Molecular Therapeutics from a “neutral” rating to an “overweight” rating and set a $20.00 target price on the stock in a report on Monday, September 14th. HC Wainwright reissued a “buy” rating and issued a $36.00 price target on shares of 4D Molecular Therapeutics in a research note on Monday, July 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research report on Friday, July 17th. Finally, The Goldman Sachs Group reiterated a “buy” rating and issued a $32.00 price objective on shares of 4D Molecular Therapeutics in a report on Thursday, August 13th.

View Our Latest Research Report on 4D Molecular Therapeutics

Insider Activity at 4D Molecular Therapeutics

In other news, insider David Kirn sold 58,333 shares of the stock in a transaction on Monday, September 14th. The stock was sold at an average price of $13.90, for a total transaction of $810,828.70. Following the completion of the transaction, the insider directly owned 767,486 shares in the company, valued at approximately $10,668,055.40. This represents a 7.06% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Over the last quarter, insiders sold 134,570 shares of company stock valued at $1,743,197. Corporate insiders own 7.90% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of FDMT. Jupiter Topco LLC purchased a new stake in shares of 4D Molecular Therapeutics in the 2nd quarter valued at approximately $76,466,000. Janus Henderson Group PLC boosted its position in shares of 4D Molecular Therapeutics by 13.2% during the 1st quarter. Janus Henderson Group PLC now owns 5,247,151 shares of the company’s stock worth $48,868,000 after purchasing an additional 611,276 shares during the period. BlackRock Inc. acquired a new stake in 4D Molecular Therapeutics in the 2nd quarter valued at approximately $60,463,000. Trails Edge Capital Partners LP acquired a new stake in 4D Molecular Therapeutics in the 2nd quarter valued at approximately $29,631,296. Finally, Armistice Capital LLC increased its holdings in 4D Molecular Therapeutics by 76.6% in the 4th quarter. Armistice Capital LLC now owns 1,936,000 shares of the company’s stock valued at $14,520,000 after purchasing an additional 840,000 shares during the last quarter. Hedge funds and other institutional investors own 99.27% of the company’s stock.

4D Molecular Therapeutics Stock Performance

NASDAQ FDMT opened at $14.71 on Friday. The stock’s fifty day moving average is $13.10 and its two-hundred day moving average is $11.04. The firm has a market capitalization of $812.58 million, a P/E ratio of -5.59 and a beta of 2.74. The company has a debt-to-equity ratio of 0.05, a quick ratio of 8.03 and a current ratio of 8.03. 4D Molecular Therapeutics has a fifty-two week low of $6.96 and a fifty-two week high of $16.93.

4D Molecular Therapeutics (NASDAQ:FDMT – Get Free Report) last issued its earnings results on Thursday, August 13th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.02). 4D Molecular Therapeutics had a negative return on equity of 41.33% and a negative net margin of 194.74%.The company had revenue of $3.78 million during the quarter, compared to analyst estimates of $3.62 million. On average, research analysts anticipate that 4D Molecular Therapeutics will post -4.07 earnings per share for the current year.

4D Molecular Therapeutics Company Profile

(Get Free Report)

4D Molecular Therapeutics, Inc is a clinical-stage biotechnology company developing genetic medicines for serious diseases with significant unmet medical needs. The company uses its Therapeutic Vector Evolution platform to engineer and select adeno-associated virus (AAV) vectors designed to deliver genetic payloads to specific tissues and support the development of potentially durable, one-time treatments.

Its research and development programs have focused primarily on ophthalmic and pulmonary diseases.

Further Reading